Ocular Therapeutix grants Tiffany Howard 200,000 stock options and 65,000 RSUs
OCUL•Ocular Therapeutix granted new executive vice president, commercial - retina Tiffany Howard options for up to 200,000 common shares and restricted stock units covering 65,000 shares, effective November 16, 2026.
1. Equity awards
The awards comprise non-statutory stock options with a 10-year term and restricted stock units. Twenty-five percent of the options vest on the grant’s first anniversary, with the remainder vesting monthly over the following three years; the RSUs vest annually over three years. Both awards require continued service through applicable vesting dates.




